|
WO2018178777A1
|
|
Process for the preparation of rifaximin crystalline form
|
|
WO2018158646A1
|
|
Rifaximin crystalline form
|
|
WO2018122724A1
|
|
Temozolomide process
|
|
WO2018100565A1
|
|
Process for the preparation of indoline compound
|
|
WO2018055496A1
|
|
Crystalline ertugliflozin process
|
|
WO2018015929A1
|
|
A novel process for the preparation of hiv protease inhibitor and intermediates thereof
|
|
WO2018011721A1
|
|
Novel polymorphic forms of ((1s,2s,3s,4r,5s))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-ethoxy-benzyl)phenyl)-6,8-dioxa-bicyclo[3.2.1]oct-1-yl-methanol
|
|
WO2017130166A1
|
|
An improved process for the preparation of highly pure anti-fibrotic drug
|
|
WO2017042735A1
|
|
Amorphous form of a hiv protease inhibitor
|
|
WO2016103232A1
|
|
An improved process for the preparation of hcv inhibitor
|
|
US2017233329A1
|
|
Process for the preparation of amino alcohol derivatives or salts thereof
|
|
CA2946101A1
|
|
An improved process for the preparation of rifamycin derivatives
|
